WILLIAM BOWLING: Open Payments
NPI 1053560979 · TEXARKANA, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,957 in 114 payments from 17 companies in 2025. Trend: 2023 $1,905 · 2024 $1,891 · 2025 $1,957
Food & beverage: $1,957
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 23 | $457 |
| ABBVIE INC. | 21 | $296 |
| Lilly USA, LLC | 14 | $253 |
| Amgen Inc. | 14 | $166 |
| Novo Nordisk Inc | 9 | $158 |
| PFIZER INC. | 10 | $136 |
| Corcept Therapeutics | 3 | $109 |
| GlaxoSmithKline, LLC. | 6 | $94 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $61 |
| Boston Scientific Corporation | 2 | $54 |
Products named: MOUNJARO, FARXIGA, BREZTRI, VRAYLAR, ELIQUIS, Korlym, OTEZLA, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
